Announces that translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American ...
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational...
Announced new durability data in metastatic colorectal cancer, demonstrating meaningful and sustained ...
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in...
Announces that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment ...
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient...
Announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration on April 16, ...
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational,...
Announced the completion of the previously announced change in the jurisdiction of incorporation of ...
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...